Screener
Theravance Biopharma TBPH EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss before income taxes | (6,470) | (14,138) |
| Provision for income tax benefit | 1,537 | 559 |
| Net loss | (4,933) | (13,579) |
| Net unrealized loss on available-for-sale investments | (123) | (7) |
| Total comprehensive loss | $(5,056) | $(13,586) |
| Net loss per share: | ||
| Net loss per share - basic and diluted | $(0.10) | $(0.27) |
| Shares used to compute net loss per share - basic and diluted | 51,279 | 49,706 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's EPS (diluted)?
- Theravance Biopharma (TBPH) reported EPS (diluted) of -$0.10 in Q1 2026.
- How has Theravance Biopharma's EPS (diluted) changed year-over-year?
- Theravance Biopharma's EPS (diluted) increased by 63.0% year-over-year, from -$0.27 to -$0.10.
- What is the long-term trend for Theravance Biopharma's EPS (diluted)?
- Over 4 years (2021 to 2025), Theravance Biopharma's EPS (diluted) has grown at a -8.9% compound annual growth rate (CAGR), from -$2.95 to $2.03.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Theravance Biopharma's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude